stockportfolio.pro
Stocks / ADCT vs EMBC
ADCT vs EMBC
ADC Therapeutics SA and Embecta Corp. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| ADC Therapeutics SA (ADCT) | Embecta Corp. (EMBC) | |
|---|---|---|
| Market cap | $0.1B | $0.2B |
| Revenue (latest FY) | $81.36M | $1.08B |
| Net income (latest FY) | $-142.62M | $95.40M |
| Revenue growth (5y CAGR) | -27.1% | -0.1% |
| Net margin | -175.3% | 8.8% |
| Return on equity | 76.7% | -14.7% |
| P/E ratio | — | 1.7 |
| Dividend yield | — | 13.9% |
| Profitable years (of last 10) | 0 | 6 |
| Positive free cash flow | No | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ADCT — free Open EMBC — freeFrequently asked questions
Which is bigger, ADCT or EMBC?
Embecta Corp. is larger by market capitalization — $0.2B versus $0.1B.
Which grows faster, ADCT or EMBC?
Over the last five fiscal years, Embecta Corp. grew revenue faster — -0.1%/yr versus -27.1%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.